Denosumab Versus Zoledronic Acid for Muscle Strength and Physical Performance in Postmenopausal Osteoporosis: A 3-Year Prospective Study. [PDF]
Li X +5 more
europepmc +1 more source
Zoledronic acid for chronic kidney disease-associated osteoporosis. [PDF]
Sakthivel S +4 more
europepmc +1 more source
Myeloid cell reprogramming combined with zoledronic acid effectively suppresses bone metastasis. [PDF]
Luo Y +8 more
europepmc +1 more source
Zoledronic Acid in the Management of Melorheostosis of Radius and Ulna - A Rare Case Report with Literature Review. [PDF]
Mallya S, Das R, Boruah DK, Puranik A.
europepmc +1 more source
Clinical characteristics and outcomes of paediatric chronic non-bacterial osteomyelitis: a retrospective cohort study with focus on zoledronic acid. [PDF]
Herman Y +9 more
europepmc +1 more source
Pseudogout attack following zoledronic acid treatment in primary hyperparathyroidism. [PDF]
Emur Gunay Y, Gunay M.
europepmc +1 more source
Zoledronic Acid-Induced Orbital Inflammation: A Diagnostic Challenge. [PDF]
Nasrini T, Bacon A, Umesh S.
europepmc +1 more source
Zoledronic acid produces analgesia by inhibiting the transient receptor potential vanilloid 1 (TRPV1) channel. [PDF]
Carvajal-Zamorano K +15 more
europepmc +1 more source
Efficacy and safety of zoledronic acid versus denosumab in the treatment of primary osteoporosis: a single-center retrospective cohort study. [PDF]
Li X +8 more
europepmc +1 more source
Papulovesicular eruption after administration of zoledronic acid: A rare cutaneous manifestation of an acute phase reaction. [PDF]
Lian SB, Liang MW, Heng YK.
europepmc +1 more source

